Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
NCT03682978 is registered in ClinicalTrials.gov with Celso Arango, MD, PhD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
- Lead sponsor
- Celso Arango, MD, PhD
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 19, 2019
- Completion date
- January 27, 2023
- Enrollment
- 124 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.